---
figid: PMC5666868__ijms-18-02187-g001
figlink: /pmc/articles/PMC5666868/figure/ijms-18-02187-f001/
number: Figure 1
caption: Glucose-inositol relationships. High glucose levels inhibit myo-Ins uptake
  by cells, by competing with SMT1/2 transporter systems. Moreover, through the activation
  of the polyol pathway, glucose extrudes myo-Ins from cells, thus “buffering” the
  increased osmolarity due to the augmented sorbitol levels. Biosynthesis of myo-Ins
  begins with G-6P enzymatic transformation into inositol-1-phosphate. However, high
  glucose levels indirectly inhibit myo-Ins biosynthesis, by increasing intracellular
  PA and consequently activating IP6K1, the principal negative regulator of myo-Ins
  de novo synthesis. Ultimately, glucose increases renal tubular catabolism and urinary
  loss of inositol through MIOX activation and overexpression. DAG, diacylglycerol;
  PKC, PKA, protein kinase C and A; G, glucose; G-6P, glucose-6-phosphate; Fru-6P,
  Fructose-6-phosphate; M, myo-inositol; IP6K1, inositol hexakisphosphate kinase;
  PA, phosphatidic acid; ISYNA1, d-3-myoinositol-phosphate synthase; IP3, inositol-3-phosphate;
  IMPA-1, inositol monophosphatase-1; MIOX, myo-inositol oxygenase; MIOXp, phosphorylated
  myo-inositol oxygenase; IP, inositol phosphate; PI, phosphatidyl-inositol; PIP2,
  phosphatidyl-inositol-4,5-biphosphate; PDK1, Pyruvate Dehydrogenase Kinase 1; AC,
  adenylate cyclase; G-PCR, G-protein coupled receptor.
pmcid: PMC5666868
papertitle: Nutritional and Acquired Deficiencies in Inositol Bioavailability. Correlations
  with Metabolic Disorders.
reftext: Simona Dinicola, et al. Int J Mol Sci. 2017 Oct;18(10):2187.
pmc_ranked_result_index: '74055'
pathway_score: 0.9725431
filename: ijms-18-02187-g001.jpg
figtitle: Glucose-inositol relationships
year: '2017'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5666868__ijms-18-02187-g001.html
  '@type': Dataset
  description: Glucose-inositol relationships. High glucose levels inhibit myo-Ins
    uptake by cells, by competing with SMT1/2 transporter systems. Moreover, through
    the activation of the polyol pathway, glucose extrudes myo-Ins from cells, thus
    “buffering” the increased osmolarity due to the augmented sorbitol levels. Biosynthesis
    of myo-Ins begins with G-6P enzymatic transformation into inositol-1-phosphate.
    However, high glucose levels indirectly inhibit myo-Ins biosynthesis, by increasing
    intracellular PA and consequently activating IP6K1, the principal negative regulator
    of myo-Ins de novo synthesis. Ultimately, glucose increases renal tubular catabolism
    and urinary loss of inositol through MIOX activation and overexpression. DAG,
    diacylglycerol; PKC, PKA, protein kinase C and A; G, glucose; G-6P, glucose-6-phosphate;
    Fru-6P, Fructose-6-phosphate; M, myo-inositol; IP6K1, inositol hexakisphosphate
    kinase; PA, phosphatidic acid; ISYNA1, d-3-myoinositol-phosphate synthase; IP3,
    inositol-3-phosphate; IMPA-1, inositol monophosphatase-1; MIOX, myo-inositol oxygenase;
    MIOXp, phosphorylated myo-inositol oxygenase; IP, inositol phosphate; PI, phosphatidyl-inositol;
    PIP2, phosphatidyl-inositol-4,5-biphosphate; PDK1, Pyruvate Dehydrogenase Kinase
    1; AC, adenylate cyclase; G-PCR, G-protein coupled receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT3
  - ADCY10
  - ADCY5
  - ADCY8
  - ADCY9
  - AKT1
  - ADCY6
  - AKT2
  - NMUR1
  - ADCY4
  - MIOX
  - ADCY7
  - TGFB3
  - ADCY3
  - ADCY2
  - TGFB1
  - TGFB2
  - ADCY1
  - IMPA1
  - ISYNA1
genes:
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY10
  entrez: '55811'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY5
  entrez: '111'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY8
  entrez: '114'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY9
  entrez: '115'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY6
  entrez: '112'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: G-PCR
  symbol: GPC-R
  source: hgnc_alias_symbol
  hgnc_symbol: NMUR1
  entrez: '10316'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY4
  entrez: '196883'
- word: MIOX
  symbol: MIOX
  source: hgnc_symbol
  hgnc_symbol: MIOX
  entrez: '55586'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY7
  entrez: '113'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY3
  entrez: '109'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY2
  entrez: '108'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY1
  entrez: '107'
- word: IMPA1
  symbol: IMPA1
  source: hgnc_symbol
  hgnc_symbol: IMPA1
  entrez: '3612'
- word: ISYNA1
  symbol: ISYNA1
  source: hgnc_symbol
  hgnc_symbol: ISYNA1
  entrez: '51477'
chemicals: []
diseases: []
---
